Palbociclib 125mg is an oral prescription medication primarily used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is part of a class of drugs known as cyclin-dependent kinase (CDK) inhibitors, specifically targeting CDK4 and CDK6, which are involved in promoting cell division.

This medication is most commonly prescribed in combination with endocrine therapy, such as letrozole or fulvestrant, and is intended for postmenopausal women or men with advanced breast cancer that has spread to other parts of the body.

Mechanism of Action

Due to the overactivation of certain proteins that regulate the cell cycle, cancer cells often grow uncontrollably. Two proteins of this kind are CDK4 and CDK6, which facilitate the cell’s transition from the G1 phase (growth phase) to the S phase (DNA synthesis phase). In breast cancer cases that are HR+/HER2-, these proteins frequently exhibit heightened activity, resulting in swift cellular division.

Palbociclib functions by selectively blocking the activity of CDK4 and CDK6, thereby effectively hindering the transition from the G1 phase to the S phase of the cell cycle. This causes the cell cycle to halt, which reduces the rate of cancer cell proliferation and may enhance the efficacy of other treatments.

Indications and Usage

Regulatory bodies like the U.S. FDA and EMA have approved Palbociclib 125mg for the following uses:

In conjunction with an aromatase inhibitor (such as letrozole): As the first-line endocrine-based treatment for postmenopausal individuals (women or men) with HR+/HER2- advanced or metastatic breast cancer.

In conjunction with fulvestrant: For patients whose disease has progressed after endocrine therapy.

One should keep in mind that palbociclib does not work against HER2-positive or triple-negative breast cancers, since it specifically targets hormone receptor pathways.

Dosage and Administration

Palbociclib 125mg is typically administered at a dosage of 125 mg, taken orally once each day for 21 days in a row. This is followed by a 7-day off-treatment period in order to complete a 28-day cycle. To aid absorption and minimize the likelihood of gastrointestinal side effects, the medication should be ingested with food.

In combination therapies, the accompanying medication (such as letrozole or fulvestrant) is administered continuously, including during the 7-day break from palbociclib. It may be necessary to adjust the dosage according to the patient’s tolerance, blood counts, or incidence of adverse reactions.

Common Side Effects

Like all cancer treatments, palbociclib may cause side effects. The most common ones include:

Neutropenia (low white blood cell count): This is the most frequently reported side effect and may increase the risk of infections.

Fatigue

Nausea

Alopecia (hair thinning or hair loss)

Diarrhea or constipation

Mouth sores (stomatitis)

Anemia or thrombocytopenia (low platelet count)

Routine blood tests are necessary to monitor for neutropenia and other hematologic changes. Dose interruptions or reductions may be required depending on lab results.

Precautions and Warnings

Infection Risk: Due to its immunosuppressive effects, palbociclib can increase the risk of infections. Patients should promptly report signs of fever, sore throat, or other signs of infection.

Pregnancy and Lactation: Palbociclib can cause harm to a developing fetus. Women who could conceive should employ effective birth control throughout treatment and for at least 3 weeks following the final dose. Breastfeeding is not recommended while on this medication.

Drug Interactions: The liver metabolizes palbociclib through CYP3A enzymes. Concomitant use with strong CYP3A inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) can affect its effectiveness or increase toxicity.

Storage and Handling

Palbociclib 125mg capsules or tablets must be stored at room temperature (20–25°C or 68–77°F) in their original packaging to safeguard them from moisture and light. Children should not have access to the medication, and it should not be shared with anyone.

Conclusion

For patients who have limited options after initial hormonal therapies, palbociclib 125mg marks a significant step forward in the treatment of HR+/HER2- metastatic breast cancer. It presents a targeted means of decelerating cancer progression and enhancing outcomes when paired with endocrine therapy by focusing on the CDK4/6 pathway.

It requires careful monitoring and should only be used under the supervision of an oncologist, like all anti-cancer drugs. When used correctly and with the right patients, palbociclib can greatly improve the quality of life and longevity of individuals suffering from advanced breast cancer.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of Palbociclib 125mg?
Palbociclib 125mg is utilized for treating hormone receptor-positive, HER2-negative breast cancer in conjunction with other drugs, including letrozole or the combination of letrozole and palbociclib. Its main application is for patients with metastatic or advanced breast cancer.

2. What is the mechanism of action of Palbociclib?
Palbociclib functions by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). Palbociclib aids in slowing cancer cell growth by impeding the action of these kinases, which are implicated in the cell cycle.

3. What is the advised dosage for Palbociclib 125mg?
Palbociclib is usually given at a dose of 125mg once daily for 21 days, followed by a 7-day break, making a total treatment cycle of 28 days. Nonetheless, it is possible to adjust the dosage based on side effects and individual patient factors.

4. What should I do if I miss a dose of Palbociclib?
If you miss a dose of Palbociclib, take it as soon as you remember, unless it is almost time for your next dose. If that is the case, omit the dose you missed and carry on with your usual dosing schedule. If you missed a dose, do not compensate by taking two doses at once.

5. Which side effects occur frequently with Palbociclib 125 mg?
Typical side effects are low white blood cell count (neutropenia), tiredness, nausea, mouth sores, and diarrhea. Due to a reduction in immune function, patients may also experience a diminished appetite, hair thinning, and infections.